Has Daniel Olson, MD received payments from drug or device companies?

Yes. Drug and device makers reported $20,405 in general payments to Daniel Olson, MD across 19 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Daniel Olson, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Daniel Olson, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Daniel Olson, MD

Hematology & Oncology · Chicago, ILNPI 1003234329

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $12,853 of the $20,405 with a category attached, or 63.0%. 9 manufacturers reported payments, led by Iovance Biotherapeutics, Inc. at 33.3% of the total. 2025 is the largest year on record at $13,367, more than ten times the $250 reported in 2019.

$20,405in general payments, 2019–2025

Across 19 payments — averaging $1073.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Iovance Biotherapeutics, Inc.$7K
Novartis$4K
Immunocore Limited$3K
E.r. Squibb & Sons, L.L.C.$3K
Springworks Therapeutics, Inc.$2K
Deciphera Pharmaceuticals Inc.$1K
plus $484 from 3 others

$2,830,691in research payments, 2019–2025

Across 28 payments — averaging $101,096 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Takeda Pharmaceuticals U.S.A., Inc.$1.7M
Merck$1M
Iovance Biotherapeutics, Inc.$97K

What the payments were for

Consulting fees$12,85363%
Speaking & faculty fees$6,77033%
Food & beverage$7834%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Iovance Biotherapeutics, Inc.	6	$6,804
Novartis	3	$3,675
Immunocore Limited	2	$3,205
E.r. Squibb & Sons, L.L.C.	1	$2,880
Springworks Therapeutics, Inc.	1	$2,188
Deciphera Pharmaceuticals Inc.	1	$1,170
Merck	2	$250
Bayer	2	$167
Janssen Research & Development, LLC	1	$67

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Amtagvi$6,659
KIMMTRAK$3,200
OGSIVEO$2,188
MEKINIST$2,100
VIMSELTINIB$1,170
KEYTRUDA$250
Vitrakvi$150

How this compares

$20,405 in reported general payments places this provider in the 80th percentile of 580 hematology & oncology providers in Illinois.

See all hematology & oncology providers in Illinois →

Medicare billing

Part B allowed, 2024

$80,234

Medicare patients

173

Services billed

688

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Imatinib Mesylate	12	$1,539
Levothyroxine Sodium	32	$288

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Chicago

Michael BishopChicago$974K
Jamile ShammoChicago$910K
Young Kwang ChaeChicago$563K
Irfan MirzaChicago$544K
Marina GarassinoChicago$397K
Chih-Yi LiaoChicago$317K
Rita NandaChicago$286K
Shuo MaChicago$280K
Santosh SarafChicago$275K
Peter RiedellChicago$273K

See the full list for Illinois →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →